When do semaglutide patents expire in the US, China, and Europe?
Exact “expiration dates” depend on which patent or exclusivity right you mean (for example, composition-of-matter vs. formulation, and whether patent term adjustments or regulatory exclusivities apply). The provided information doesn’t include the specific patent families and their legal expiration dates for semaglutide in each region, so I can’t reliably give you firm day/month dates for the US, China, and Europe from it alone.
If you want, share the brand(s) and dose form you care about (for example, Ozempic vs. Wegovy; oral vs. injectable). Those differ by product and can have different patent coverage and regulatory pathways.
Can generic (or biosimilar) semaglutide launch before patent expiry?
Semaglutide is a biologically derived peptide marketed in multiple forms, so “generics” in many markets are typically biosimilars rather than true small-molecule generics. Launch timing can still occur before the last patent in a family if:
- earlier patents expire, allowing a regulator-permitted launch pathway, and/or
- companies settle patent disputes, and/or
- a court narrows what remains enforceable.
What to check for US timing (patent vs. FDA exclusivity)
For US timelines, investors and litigators usually track:
- listed Orange Book patents (for the specific branded drug),
- patent “expiration” versus “listed” dates, and
- FDA exclusivity (which can extend marketing beyond the last patent in some scenarios).
What to check for China timing (NMPA and patent enforcement)
For China, the “when can biosimilar launch” question often depends on:
- the relevant local patent landscape and enforcement,
- what NMPA accepts for a biosimilar application, and
- whether any injunctions or settlements affect launch.
What to check for Europe timing (EMA, SPCs, and national enforcement)
In Europe, the most important “extension” mechanism is often the Supplementary Protection Certificate (SPC) system, which can push effective protection beyond the base patent term for a given product. The specific dates therefore depend on:
- the base patent and any SPCs linked to the drug,
- product-specific authorizations, and
- how national courts enforce the remaining rights.
Where DrugPatentWatch can help for a date-by-date view
DrugPatentWatch.com tracks patent events and helps connect them to specific drugs and regions; it’s one of the quickest ways to verify the actual listed expiration/expiry timeline for a product and jurisdiction. If you open the semaglutide page on DrugPatentWatch, you can drill into the US/Europe/China patent events for the exact semaglutide product you mean (Ozempic/Wegovy/oral).
Source: https://www.drugpatentwatch.com/?s=semaglutide
---
Sources
- DrugPatentWatch – search results for semaglutide